SlideShare a Scribd company logo
1 of 6
PRESENTATION ON DRUG AND THERAPEUTICS COMMITTEES (DTC), PEER REVIEW WORKSHOP
ON BETTER MEDICINES FOR CHILDREN.FROM 14TH TO 16TH DECEMBER, 2011 BY THE BONGO
DISTRICT HOSPITAL, U.E.R.
THEME : MAKING CHILD MEDICINES FRIENDLY AND ACCESSIBLY ACCORDING TO MY LOCAL NEEDS.
1. FRIENDLY - INTHIS CONTEXT, MEANS THE MEDICINEBYPERSENTATIONSHOULD BE
ATTRACTIVE,COSTEFFECTIVE,POPULARINAMONGST EVENPOORHOUSEHOLDS,LONGERSHELF-
LIFE,STABLEUNDERNORMAL STORAGECONDITIONS,CHILD-CAPPED PROTECTED,EASILYTO BE
IDENTIFIED FROM FAKEAND IMMITATED BRANDS BEFORETHEYGET ONTO OUR SHELVES,HAS
GRADUATED MEASURING CUPS FORDISPENSING ACCORDING TO CHILD’S BODYWEIGHT ORBODY
SURFACEAREA AND NOT BY THERAPEUTIC DOSAGE- RANGES; FOREXAMPLE, 1 TO 5 YEARS CAN USE
THE SAME PRESENTATIONOF PARACETAMOL SYPRUP BUT THATDOES NOT MEAN 1 YEAR CHILD
SHOULD BE GIVENA 5 YEAR’S OLD DOSAGE.
2. ACCESSIBLE– INTHIS CONTEXT, MEANS WHO OWNS THE PATENCY TO MANUFACTUREAND
DISTRIBUTEFROMAFARORNEAR, AND AT WHATPACE? CAN THIS PATENCY HOLDERAGREETO SHARE
WITH OTHERMANUFACTURES WHEN DEMANDS ARE BEYOND THE SCOPE? WILL THELOGISTICS
MANAGEMENT INFORMATIONSERVICES BEINDEPENDENTOF PARTISANPOLITICS AND FROMALL
STATES’ OR LOCAL GOVERNMENT’S BUREAUCRACY?
3. FOR SELECTED DISEASEAREA - INTHIS CONTEXT,: ACCORDING TO MYLOCAL NEEDS.BONGO DISTRICT
HOSPITAL FALLS WITHINTWO EXTREMED SEASONS: A SIX MONTHS OF DRY,DUSTY,WINDY,VERYHOT
HARMATTAN SEASONAND A SIX MONTHS OF RAINFALLS. SO WEDO EXPERIENCE
DYSENTERY,THYPHOID,CEREBROSPINAL MENINGITIS,SEVEREMALARIA,SEVERE
ANAEMIA,MARASMUS,RESPIRATORYDISTRESS SYDROMMEINNEW BORNS,ASHMATIC
ATTACKS,SEPTICAEMIA AND OTHERS. SO I DO THENASK MYSELF, WHENITCOMES TO PROCUREMENT
ISSUES, WHAT MIDICINES FORNEONATES, INFANTS’AND CHILDRENAREAPPROPRIATEFORTHE
RESPECTIVECONDITIONS LISTED ABOVE? FOREXAMPLE, WHICH TYPEOF ORAL REHYDRATIONSALTS
(O.R.S.) SHALL I NEED? A SLIGHTLYSURGERY, LEMONOR ORANGE FLAVOURED O.R.S. ORTHE
POPULARNORMAL OR PLAINTYPE? THE CIPROFLOXACIN250MG, IS ITSCORED TO BE DIVIDED ORI
NEED TO FIND ANINNOVATIONOF THE125MG TYPE? WHATABOUTA STABLE SUSPENION
FORMULATION FORINFANTS WHOCAN NOTSWALLOW ORDETESTS THE TASTE AND SCENT OF A
DISSOLVED TABLET? WHATABOUTTAKING INTO CONSIDERATIONTENDINITIESISSUEINSOME
DISEASE-PRONED CHILDREN?
PANEL DISCUSSIONS
SUCCESSES AND CHALLENGES OF DTCs IN BONGO DISTRICTHOSPITAL AREOUTLINED AS:
1. SUCCESSES –
A. A TREMENDOUS IMPROVEMENTINRATIONAL DRUG USEINDICATORS. CONSTANTLYRAISING THEAWARENESS
THAT THE PHARMACIST, EVENTHOUGH DOES NOTFORMPART OF THE PRESCRIBING TEAMINTHE CONSULTING
ROOM, HE/SHEHAS MUCH TRAINING ONDRUGS MANAGEMENT THANTHE PRESCRIBERS, AND ALSO
PHARMACISTS HAVETHERIGHT TO INTERVENEINTHE MODEAND COSTOF TREATMENTS.
B. PERSISTENTLYPROVIDING PRESCRIBERS WITH ESSENTIAL MEDICINES LISTBYGENERICNAMES.
C. MEMORANDUMS ON THE STATE OF DRUGS’ STOCKS USING THELIFO,FIFO,NIFOPRINCIPLES.
D. CONSTANTLY VISITING THECONSULTING ROOMSWITH MATTERS PERTAINING TO IRRATIONAL
PRESCRIPTIONS.
E. PROCURING DRUGS MEETING THE NEED OF ALL CATEGORIES OF PATIENTS TO MINIMISE
THE CUTTING OF TABLETS UNDER UN-FAVOURABLECONDITIONS.
F. CONVEYANCEOF DTCs MEETINGS WITH THEPHARMACISTAS SECRETARY.
2. CHALLENGES –
A. THE PHARMACISTNOTCHAIR-PERSONATDTCs’ MEETING MEANS LESS FOCAL INDECISION
MAKING.
B. LESS AVAILABLETIMEFORMEETINGS
C. PRESCRIBERS VIEW SUCH MEETING AS GROUND TO BACKLASH THEMHENCE MUCH EXCUSSES
FORNOT BEING ABLE TO BE PRESENT.
D. SNACKS ARE DIFFICULTTO ARRANGEFOR, BECAUSE EVERYONE IS AFRAID TO TEMPERWITH
DRUG REVOLVING FUND.
E. DRUGS NON-AVAILABILITYCOUPLED WITH NO FUNDS TO MOMENTARILYPROCURE DRUGS
DIS-ORGANISES PLANS AND MODALITIES SETUP AT DTCs’ MEETINGS.
ROLES OF DTCs IN ENSURING BETTER MEDICINES FOR CHILDREN.
1. TRY TO FIND OUTFROMRECORDS AND CONSULTING ROOMS THENUMBER OF ALL
CATEGORIES OF CHILDRENTREATED ATPARTICULARTIMEOF THE YEAR BY DIAGNOSIS. THIS
WILL HELP TO DETERMINETHE CONSUMPTIONPATTERNOF CERTAINDRUGS FOR
PROCUREMENT PURPOSES.
2. ALWAYS INVESTIGATING THESTATE OF DRUG REVOLVING FUND ATACCOUNT’S UNIT.
3. TO ALERT PRESCRIBERS ONDRUGS WHICH AREABOUT TO EXPIREONMONTHLYBASIS.
4. TO HELP STREAMLINETHE DURATION OF THERAPYBY PRESCRIBERS.
5. TO MINIMISESYDROMMICTREATMENTS AS A WAY OF CHECKING THEPRESCRIBING OF TWO
DRUGS OF COMMONPHARMACOLOGICAL EFFECTS (ACTIVITIES) FORTHESAMESYMPTOMS.
ETC.
USE OF ZINC DISPERSABLETABLETS IN THE TREATMENTOF DIARRHOEA IN CHILDRENUNDER 5
YEARS OF AGE:
ZINCDISPERSABLETABLETCOMES INTHE FORMOF SULPHATEBY COMPOUNDING. ITIS
DIRECTED TO BE ADMINISTERED WITH ORAL REHYDRATIONSALT; PROBABLYDUETO FACT
THAT ZINC SULPHATEHAS AN ASTRINGENTPROPERTY.
THERE IS THE NEED TO HAVETHIS PRODUCT INA STREEGTH WHICH CANBE USED FOR
TREATING CHILDRENABOVE5 YEARS AND AS WELL AS ADULTS.
PRESCRIPTION AUDITDISSEMINATION OF PRELIMINARY RESULTS.
PRESCRIBING TEAMIS COMPOSED OF THEFOLLOWING;
1. THE MEDICAL SUPERINTENDENTOFFICER.
2. MEDICAL DOCTORS.
3. PHYSICIANASSISTANTS.
4. PRESCRIBING - NURSES .
5. ETC.
DEPENDING ONTHEFINDINGS, PRELIMINARYRESULTS SHOULD BECLASSIFIED INTO THE
ABOVECATEGORIES OF PRESCRIBERS BEFORE BEING DISSSEMINATED TO AVOID THE
DESTRUCTIONOF THECONFIDENCEOF A FELLOW PRESCRIBER INOTHERPRESCRIBERS.
NO NEED FORNAMING AND SHAMING. PRESCRIBERS MUSTRECIPROCATETHISFINE
GESTURE OF RESPECT BY PHARMACISTS WITH HUMILITYAND SINCERITY.
TRENDS IN ANTIBIOTIC RESISTANCEIN GHANA.
 POORCOMPLIANCEONTHEPART OF PATIENTS.
 WRONGFUL INDICATIONS.
 GENERAL DRUG ABUSE BY GENERAL PUBLIC. FOREXAMPLENEVER SATISFIED IF
TREATMENT DOES NOTCONTAININJECTABLES.
 FLAWS INTHE REGULATORYSYSTEM INPROCUREMENT; THE STORAGEAND DISPENSING.
 POLYPHARMACYISSUES.
 AVAILABILITY, AFFORDABILITY, ETC.
 NON AVAILABILITY OF APPROPRIATESTRENGTH FORNEONATES, GERIATRICS FOR
EXAMPLE, SUSPENSIONAMOXICILLIN+CLAVULANICACID 156.25MG/5ML-70MLS,SYRUP
GRISEOFULVIN125MG/5ML-100ML, SUSPENSIONFLUCONAZOLE50MG/5ML-35ML,ETC. AT
THE REGIONAL MEDICAL STORES.
PREPARED BY: Kweku-Duah Humphrey Nartey. AT THE BONGO DISTRICTHOSPITAL.DATED
ON 11TH
OF DECEMBER, 2011.
TELEPHONE NUMBER: 0207759000 OR 0267759000.
e - mail address: humphgh@yahoo.com

More Related Content

Viewers also liked

The nature lover’s guide to cybersecurity
The nature lover’s guide to cybersecurityThe nature lover’s guide to cybersecurity
The nature lover’s guide to cybersecurity
Sherry Jones
 
Estrategia de Mercadotecnia Digital
Estrategia de Mercadotecnia DigitalEstrategia de Mercadotecnia Digital
Estrategia de Mercadotecnia Digital
Ali1114
 

Viewers also liked (17)

Jaysoncv
JaysoncvJaysoncv
Jaysoncv
 
Zongrone Project 2 Mood board
Zongrone Project 2 Mood boardZongrone Project 2 Mood board
Zongrone Project 2 Mood board
 
The Stairway - Analysis
The Stairway - AnalysisThe Stairway - Analysis
The Stairway - Analysis
 
Jaber_DBA
Jaber_DBAJaber_DBA
Jaber_DBA
 
Refining charts using Adobe Illustrator
Refining charts using Adobe IllustratorRefining charts using Adobe Illustrator
Refining charts using Adobe Illustrator
 
The nature lover’s guide to cybersecurity
The nature lover’s guide to cybersecurityThe nature lover’s guide to cybersecurity
The nature lover’s guide to cybersecurity
 
Procesos publicitat
Procesos publicitatProcesos publicitat
Procesos publicitat
 
Duvan romero 1
Duvan romero 1Duvan romero 1
Duvan romero 1
 
Presentation1
Presentation1Presentation1
Presentation1
 
A previously unknown and recently recovered Brussels altarpiece (1470-90) in ...
A previously unknown and recently recovered Brussels altarpiece (1470-90) in ...A previously unknown and recently recovered Brussels altarpiece (1470-90) in ...
A previously unknown and recently recovered Brussels altarpiece (1470-90) in ...
 
resume dt.01102015
resume dt.01102015resume dt.01102015
resume dt.01102015
 
Mr. Bernard Green Speaker at Knowledge Day 2015
Mr. Bernard Green Speaker at Knowledge Day 2015Mr. Bernard Green Speaker at Knowledge Day 2015
Mr. Bernard Green Speaker at Knowledge Day 2015
 
Estrategia de Mercadotecnia Digital
Estrategia de Mercadotecnia DigitalEstrategia de Mercadotecnia Digital
Estrategia de Mercadotecnia Digital
 
Storm procurement global sourcing presentation
Storm procurement global sourcing presentationStorm procurement global sourcing presentation
Storm procurement global sourcing presentation
 
Seven things to highlight about your teaching practice
Seven things to highlight about your teaching practiceSeven things to highlight about your teaching practice
Seven things to highlight about your teaching practice
 
Adwebmaroc Veille web et RS / Gestion de crise
Adwebmaroc Veille web et RS / Gestion de criseAdwebmaroc Veille web et RS / Gestion de crise
Adwebmaroc Veille web et RS / Gestion de crise
 
Lluc colomo-tfm-decisiones-de-riesgo-genero
Lluc colomo-tfm-decisiones-de-riesgo-generoLluc colomo-tfm-decisiones-de-riesgo-genero
Lluc colomo-tfm-decisiones-de-riesgo-genero
 

Similar to PRESENTATION ON DRUG AND THERAPEUTICS COMMITTEES(1)

EVIDENCE BASED PROJECTRECOMMENDING AN EVIDENCE-BASED PRA.docx
EVIDENCE BASED PROJECTRECOMMENDING AN EVIDENCE-BASED PRA.docxEVIDENCE BASED PROJECTRECOMMENDING AN EVIDENCE-BASED PRA.docx
EVIDENCE BASED PROJECTRECOMMENDING AN EVIDENCE-BASED PRA.docx
elbanglis
 
A Comparative Study of Cost Effectiveness of Ibuprofen Suspensions with Other...
A Comparative Study of Cost Effectiveness of Ibuprofen Suspensions with Other...A Comparative Study of Cost Effectiveness of Ibuprofen Suspensions with Other...
A Comparative Study of Cost Effectiveness of Ibuprofen Suspensions with Other...
iosrjce
 
Medication Use Evaluation-2015
Medication Use Evaluation-2015Medication Use Evaluation-2015
Medication Use Evaluation-2015
Maura Andary
 
Crofelemer letter salix and napo 2012
Crofelemer letter salix and napo 2012Crofelemer letter salix and napo 2012
Crofelemer letter salix and napo 2012
Bhumi Patel
 
Eficacia manejo de tratamiento responsabilidad uso medicamentos - CICATSALUD
Eficacia manejo de tratamiento   responsabilidad uso medicamentos - CICATSALUDEficacia manejo de tratamiento   responsabilidad uso medicamentos - CICATSALUD
Eficacia manejo de tratamiento responsabilidad uso medicamentos - CICATSALUD
CICAT SALUD
 
I N J U R Y P R E V E N T I O NAnna ValdeWalden UnFo.docx
I N J U R Y P R E V E N T I O NAnna ValdeWalden UnFo.docxI N J U R Y P R E V E N T I O NAnna ValdeWalden UnFo.docx
I N J U R Y P R E V E N T I O NAnna ValdeWalden UnFo.docx
wilcockiris
 
Síndome de L-N.pdf
Síndome de L-N.pdfSíndome de L-N.pdf
Síndome de L-N.pdf
NAPA11
 
Newlogo presentation
Newlogo presentationNewlogo presentation
Newlogo presentation
vincenthessey
 

Similar to PRESENTATION ON DRUG AND THERAPEUTICS COMMITTEES(1) (20)

EVIDENCE BASED PROJECTRECOMMENDING AN EVIDENCE-BASED PRA.docx
EVIDENCE BASED PROJECTRECOMMENDING AN EVIDENCE-BASED PRA.docxEVIDENCE BASED PROJECTRECOMMENDING AN EVIDENCE-BASED PRA.docx
EVIDENCE BASED PROJECTRECOMMENDING AN EVIDENCE-BASED PRA.docx
 
Pediatric safety ppt 1
Pediatric safety ppt 1Pediatric safety ppt 1
Pediatric safety ppt 1
 
Introduction to clinical research
Introduction to clinical researchIntroduction to clinical research
Introduction to clinical research
 
REVERSE PHARMACOLOGY & DRUG DISCOVERY
REVERSE PHARMACOLOGY & DRUG DISCOVERYREVERSE PHARMACOLOGY & DRUG DISCOVERY
REVERSE PHARMACOLOGY & DRUG DISCOVERY
 
A Comparative Study of Cost Effectiveness of Ibuprofen Suspensions with Other...
A Comparative Study of Cost Effectiveness of Ibuprofen Suspensions with Other...A Comparative Study of Cost Effectiveness of Ibuprofen Suspensions with Other...
A Comparative Study of Cost Effectiveness of Ibuprofen Suspensions with Other...
 
Lecture # 03 New Drug Approval and Development Process
Lecture # 03 New Drug Approval and Development ProcessLecture # 03 New Drug Approval and Development Process
Lecture # 03 New Drug Approval and Development Process
 
Medication Use Evaluation-2015
Medication Use Evaluation-2015Medication Use Evaluation-2015
Medication Use Evaluation-2015
 
Crofelemer letter salix and napo 2012
Crofelemer letter salix and napo 2012Crofelemer letter salix and napo 2012
Crofelemer letter salix and napo 2012
 
Translation of Orphan DiseaseTrial Design into General Drug Development
Translation of Orphan DiseaseTrial Design into General Drug DevelopmentTranslation of Orphan DiseaseTrial Design into General Drug Development
Translation of Orphan DiseaseTrial Design into General Drug Development
 
Eficacia manejo de tratamiento responsabilidad uso medicamentos - CICATSALUD
Eficacia manejo de tratamiento   responsabilidad uso medicamentos - CICATSALUDEficacia manejo de tratamiento   responsabilidad uso medicamentos - CICATSALUD
Eficacia manejo de tratamiento responsabilidad uso medicamentos - CICATSALUD
 
Risk_Trends_2015
Risk_Trends_2015Risk_Trends_2015
Risk_Trends_2015
 
genetic osce for dnb pdiatric
genetic osce for dnb pdiatricgenetic osce for dnb pdiatric
genetic osce for dnb pdiatric
 
(2102 2112) nd14
(2102 2112) nd14(2102 2112) nd14
(2102 2112) nd14
 
I N J U R Y P R E V E N T I O NAnna ValdeWalden UnFo.docx
I N J U R Y P R E V E N T I O NAnna ValdeWalden UnFo.docxI N J U R Y P R E V E N T I O NAnna ValdeWalden UnFo.docx
I N J U R Y P R E V E N T I O NAnna ValdeWalden UnFo.docx
 
Síndome de L-N.pdf
Síndome de L-N.pdfSíndome de L-N.pdf
Síndome de L-N.pdf
 
Síndome de L-N.pdf
Síndome de L-N.pdfSíndome de L-N.pdf
Síndome de L-N.pdf
 
Ontario Pharmacy Technician Prescription Entering
Ontario Pharmacy Technician Prescription EnteringOntario Pharmacy Technician Prescription Entering
Ontario Pharmacy Technician Prescription Entering
 
SafetyPharmacology.pptx
SafetyPharmacology.pptxSafetyPharmacology.pptx
SafetyPharmacology.pptx
 
Newlogo presentation
Newlogo presentationNewlogo presentation
Newlogo presentation
 
GR AFHS Polypharmacy.w-o CH.pptx
GR AFHS Polypharmacy.w-o CH.pptxGR AFHS Polypharmacy.w-o CH.pptx
GR AFHS Polypharmacy.w-o CH.pptx
 

PRESENTATION ON DRUG AND THERAPEUTICS COMMITTEES(1)

  • 1. PRESENTATION ON DRUG AND THERAPEUTICS COMMITTEES (DTC), PEER REVIEW WORKSHOP ON BETTER MEDICINES FOR CHILDREN.FROM 14TH TO 16TH DECEMBER, 2011 BY THE BONGO DISTRICT HOSPITAL, U.E.R. THEME : MAKING CHILD MEDICINES FRIENDLY AND ACCESSIBLY ACCORDING TO MY LOCAL NEEDS. 1. FRIENDLY - INTHIS CONTEXT, MEANS THE MEDICINEBYPERSENTATIONSHOULD BE ATTRACTIVE,COSTEFFECTIVE,POPULARINAMONGST EVENPOORHOUSEHOLDS,LONGERSHELF- LIFE,STABLEUNDERNORMAL STORAGECONDITIONS,CHILD-CAPPED PROTECTED,EASILYTO BE IDENTIFIED FROM FAKEAND IMMITATED BRANDS BEFORETHEYGET ONTO OUR SHELVES,HAS GRADUATED MEASURING CUPS FORDISPENSING ACCORDING TO CHILD’S BODYWEIGHT ORBODY SURFACEAREA AND NOT BY THERAPEUTIC DOSAGE- RANGES; FOREXAMPLE, 1 TO 5 YEARS CAN USE THE SAME PRESENTATIONOF PARACETAMOL SYPRUP BUT THATDOES NOT MEAN 1 YEAR CHILD SHOULD BE GIVENA 5 YEAR’S OLD DOSAGE. 2. ACCESSIBLE– INTHIS CONTEXT, MEANS WHO OWNS THE PATENCY TO MANUFACTUREAND DISTRIBUTEFROMAFARORNEAR, AND AT WHATPACE? CAN THIS PATENCY HOLDERAGREETO SHARE WITH OTHERMANUFACTURES WHEN DEMANDS ARE BEYOND THE SCOPE? WILL THELOGISTICS MANAGEMENT INFORMATIONSERVICES BEINDEPENDENTOF PARTISANPOLITICS AND FROMALL STATES’ OR LOCAL GOVERNMENT’S BUREAUCRACY? 3. FOR SELECTED DISEASEAREA - INTHIS CONTEXT,: ACCORDING TO MYLOCAL NEEDS.BONGO DISTRICT HOSPITAL FALLS WITHINTWO EXTREMED SEASONS: A SIX MONTHS OF DRY,DUSTY,WINDY,VERYHOT
  • 2. HARMATTAN SEASONAND A SIX MONTHS OF RAINFALLS. SO WEDO EXPERIENCE DYSENTERY,THYPHOID,CEREBROSPINAL MENINGITIS,SEVEREMALARIA,SEVERE ANAEMIA,MARASMUS,RESPIRATORYDISTRESS SYDROMMEINNEW BORNS,ASHMATIC ATTACKS,SEPTICAEMIA AND OTHERS. SO I DO THENASK MYSELF, WHENITCOMES TO PROCUREMENT ISSUES, WHAT MIDICINES FORNEONATES, INFANTS’AND CHILDRENAREAPPROPRIATEFORTHE RESPECTIVECONDITIONS LISTED ABOVE? FOREXAMPLE, WHICH TYPEOF ORAL REHYDRATIONSALTS (O.R.S.) SHALL I NEED? A SLIGHTLYSURGERY, LEMONOR ORANGE FLAVOURED O.R.S. ORTHE POPULARNORMAL OR PLAINTYPE? THE CIPROFLOXACIN250MG, IS ITSCORED TO BE DIVIDED ORI NEED TO FIND ANINNOVATIONOF THE125MG TYPE? WHATABOUTA STABLE SUSPENION FORMULATION FORINFANTS WHOCAN NOTSWALLOW ORDETESTS THE TASTE AND SCENT OF A DISSOLVED TABLET? WHATABOUTTAKING INTO CONSIDERATIONTENDINITIESISSUEINSOME DISEASE-PRONED CHILDREN? PANEL DISCUSSIONS SUCCESSES AND CHALLENGES OF DTCs IN BONGO DISTRICTHOSPITAL AREOUTLINED AS: 1. SUCCESSES – A. A TREMENDOUS IMPROVEMENTINRATIONAL DRUG USEINDICATORS. CONSTANTLYRAISING THEAWARENESS THAT THE PHARMACIST, EVENTHOUGH DOES NOTFORMPART OF THE PRESCRIBING TEAMINTHE CONSULTING ROOM, HE/SHEHAS MUCH TRAINING ONDRUGS MANAGEMENT THANTHE PRESCRIBERS, AND ALSO PHARMACISTS HAVETHERIGHT TO INTERVENEINTHE MODEAND COSTOF TREATMENTS.
  • 3. B. PERSISTENTLYPROVIDING PRESCRIBERS WITH ESSENTIAL MEDICINES LISTBYGENERICNAMES. C. MEMORANDUMS ON THE STATE OF DRUGS’ STOCKS USING THELIFO,FIFO,NIFOPRINCIPLES. D. CONSTANTLY VISITING THECONSULTING ROOMSWITH MATTERS PERTAINING TO IRRATIONAL PRESCRIPTIONS. E. PROCURING DRUGS MEETING THE NEED OF ALL CATEGORIES OF PATIENTS TO MINIMISE THE CUTTING OF TABLETS UNDER UN-FAVOURABLECONDITIONS. F. CONVEYANCEOF DTCs MEETINGS WITH THEPHARMACISTAS SECRETARY. 2. CHALLENGES – A. THE PHARMACISTNOTCHAIR-PERSONATDTCs’ MEETING MEANS LESS FOCAL INDECISION MAKING. B. LESS AVAILABLETIMEFORMEETINGS C. PRESCRIBERS VIEW SUCH MEETING AS GROUND TO BACKLASH THEMHENCE MUCH EXCUSSES FORNOT BEING ABLE TO BE PRESENT. D. SNACKS ARE DIFFICULTTO ARRANGEFOR, BECAUSE EVERYONE IS AFRAID TO TEMPERWITH DRUG REVOLVING FUND. E. DRUGS NON-AVAILABILITYCOUPLED WITH NO FUNDS TO MOMENTARILYPROCURE DRUGS DIS-ORGANISES PLANS AND MODALITIES SETUP AT DTCs’ MEETINGS. ROLES OF DTCs IN ENSURING BETTER MEDICINES FOR CHILDREN. 1. TRY TO FIND OUTFROMRECORDS AND CONSULTING ROOMS THENUMBER OF ALL CATEGORIES OF CHILDRENTREATED ATPARTICULARTIMEOF THE YEAR BY DIAGNOSIS. THIS
  • 4. WILL HELP TO DETERMINETHE CONSUMPTIONPATTERNOF CERTAINDRUGS FOR PROCUREMENT PURPOSES. 2. ALWAYS INVESTIGATING THESTATE OF DRUG REVOLVING FUND ATACCOUNT’S UNIT. 3. TO ALERT PRESCRIBERS ONDRUGS WHICH AREABOUT TO EXPIREONMONTHLYBASIS. 4. TO HELP STREAMLINETHE DURATION OF THERAPYBY PRESCRIBERS. 5. TO MINIMISESYDROMMICTREATMENTS AS A WAY OF CHECKING THEPRESCRIBING OF TWO DRUGS OF COMMONPHARMACOLOGICAL EFFECTS (ACTIVITIES) FORTHESAMESYMPTOMS. ETC. USE OF ZINC DISPERSABLETABLETS IN THE TREATMENTOF DIARRHOEA IN CHILDRENUNDER 5 YEARS OF AGE: ZINCDISPERSABLETABLETCOMES INTHE FORMOF SULPHATEBY COMPOUNDING. ITIS DIRECTED TO BE ADMINISTERED WITH ORAL REHYDRATIONSALT; PROBABLYDUETO FACT THAT ZINC SULPHATEHAS AN ASTRINGENTPROPERTY. THERE IS THE NEED TO HAVETHIS PRODUCT INA STREEGTH WHICH CANBE USED FOR TREATING CHILDRENABOVE5 YEARS AND AS WELL AS ADULTS. PRESCRIPTION AUDITDISSEMINATION OF PRELIMINARY RESULTS. PRESCRIBING TEAMIS COMPOSED OF THEFOLLOWING; 1. THE MEDICAL SUPERINTENDENTOFFICER.
  • 5. 2. MEDICAL DOCTORS. 3. PHYSICIANASSISTANTS. 4. PRESCRIBING - NURSES . 5. ETC. DEPENDING ONTHEFINDINGS, PRELIMINARYRESULTS SHOULD BECLASSIFIED INTO THE ABOVECATEGORIES OF PRESCRIBERS BEFORE BEING DISSSEMINATED TO AVOID THE DESTRUCTIONOF THECONFIDENCEOF A FELLOW PRESCRIBER INOTHERPRESCRIBERS. NO NEED FORNAMING AND SHAMING. PRESCRIBERS MUSTRECIPROCATETHISFINE GESTURE OF RESPECT BY PHARMACISTS WITH HUMILITYAND SINCERITY. TRENDS IN ANTIBIOTIC RESISTANCEIN GHANA.  POORCOMPLIANCEONTHEPART OF PATIENTS.  WRONGFUL INDICATIONS.  GENERAL DRUG ABUSE BY GENERAL PUBLIC. FOREXAMPLENEVER SATISFIED IF TREATMENT DOES NOTCONTAININJECTABLES.  FLAWS INTHE REGULATORYSYSTEM INPROCUREMENT; THE STORAGEAND DISPENSING.  POLYPHARMACYISSUES.  AVAILABILITY, AFFORDABILITY, ETC.  NON AVAILABILITY OF APPROPRIATESTRENGTH FORNEONATES, GERIATRICS FOR EXAMPLE, SUSPENSIONAMOXICILLIN+CLAVULANICACID 156.25MG/5ML-70MLS,SYRUP GRISEOFULVIN125MG/5ML-100ML, SUSPENSIONFLUCONAZOLE50MG/5ML-35ML,ETC. AT THE REGIONAL MEDICAL STORES.
  • 6. PREPARED BY: Kweku-Duah Humphrey Nartey. AT THE BONGO DISTRICTHOSPITAL.DATED ON 11TH OF DECEMBER, 2011. TELEPHONE NUMBER: 0207759000 OR 0267759000. e - mail address: humphgh@yahoo.com